309 related articles for article (PubMed ID: 28808886)
41. Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects.
Wang X; Zhang ZY; Arora S; Wang J; Lu S; Powers D; Kansra V
J Clin Pharmacol; 2018 Aug; 58(8):1074-1083. PubMed ID: 29693712
[TBL] [Abstract][Full Text] [Related]
42. Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus).
Uehara S; Inoue T; Utoh M; Toda A; Shimizu M; Uno Y; Sasaki E; Yamazaki H
Xenobiotica; 2016; 46(2):163-8. PubMed ID: 26114209
[TBL] [Abstract][Full Text] [Related]
43. Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.
Lenuzza N; Duval X; Nicolas G; Thévenot E; Job S; Videau O; Narjoz C; Loriot MA; Beaune P; Becquemont L; Mentré F; Funck-Brentano C; Alavoine L; Arnaud P; Delaforge M; Bénech H
Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):125-38. PubMed ID: 25465228
[TBL] [Abstract][Full Text] [Related]
44. A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
Treijtel N; Collins C; van Bruijnsvoort M; Fuhr R; Ernault E; Gangaram-Panday S; Passier P
Clin Pharmacol Drug Dev; 2019 May; 8(4):529-540. PubMed ID: 30730615
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives.
Groen-Wijnberg M; van Dijk J; Krauwinkel W; Kerbusch V; Meijer J; Tretter R; Zhang W; van Gelderen M
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):417-429. PubMed ID: 27350625
[TBL] [Abstract][Full Text] [Related]
46. Inhibitory effects of kale ingestion on metabolism by cytochrome P450 enzymes in rats.
Yamasaki I; Yamada M; Uotsu N; Teramoto S; Takayanagi R; Yamada Y
Biomed Res; 2012; 33(4):235-42. PubMed ID: 22975634
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.
Sathe AG; Othman AA; Mohamed MF
J Clin Pharmacol; 2021 Mar; 61(3):307-318. PubMed ID: 32960975
[TBL] [Abstract][Full Text] [Related]
48. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
[TBL] [Abstract][Full Text] [Related]
49. Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?
Lammers LA; Achterbergh R; Romijn JA; Mathôt RAA
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):251-257. PubMed ID: 28929443
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Johansson S; Read J; Oliver S; Steinberg M; Li Y; Lisbon E; Mathews D; Leese PT; Martin P
Clin Pharmacokinet; 2014 Sep; 53(9):837-47. PubMed ID: 25117183
[TBL] [Abstract][Full Text] [Related]
51. Modulation of CYP450 Activities in Patients With Type 2 Diabetes.
Gravel S; Chiasson JL; Turgeon J; Grangeon A; Michaud V
Clin Pharmacol Ther; 2019 Dec; 106(6):1280-1289. PubMed ID: 31099895
[TBL] [Abstract][Full Text] [Related]
52. Drug-Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers.
Nakamura T; Shimizu H; Kawaguchi A
Clin Ther; 2020 Nov; 42(11):2171-2183.e4. PubMed ID: 33153727
[TBL] [Abstract][Full Text] [Related]
53. Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects.
Chong E; Kalia V; Willsie S; Winkle P
J Nephrol; 2014 Dec; 27(6):659-66. PubMed ID: 24699894
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach.
Cusinato DAC; Martinez EZ; Cintra MTC; Filgueira GCO; Berretta AA; Lanchote VL; Coelho EB
J Ethnopharmacol; 2019 Dec; 245():112174. PubMed ID: 31442620
[TBL] [Abstract][Full Text] [Related]
55. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
[TBL] [Abstract][Full Text] [Related]
56. Clinical drug interaction profile of idelalisib in healthy subjects.
Jin F; Robeson M; Zhou H; Moyer C; Wilbert S; Murray B; Ramanathan S
J Clin Pharmacol; 2015 Aug; 55(8):909-19. PubMed ID: 25760671
[TBL] [Abstract][Full Text] [Related]
57. Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Khatri A; Cheng L; Camez A; Ignatenko S; Pang Y; Othman AA
Clin Pharmacokinet; 2019 Jun; 58(6):805-814. PubMed ID: 30574672
[TBL] [Abstract][Full Text] [Related]
58. Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Ottesen LH; Li Y; Mugundu GM
Cancer Chemother Pharmacol; 2023 Sep; 92(3):193-203. PubMed ID: 37394627
[TBL] [Abstract][Full Text] [Related]
59. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of Drug-Drug Interaction Potential of Enarodustat (JTZ-951) Using a Cytochrome P450 Probe Cocktail.
Pai SM; Yamada H; Murata H
Clin Pharmacol Drug Dev; 2023 Jul; 12(7):667-682. PubMed ID: 37269147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]